JNJ-26146900
A detailed overview of the investigational drug JNJ-26146900
JNJ-26146900 is an investigational drug developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is being studied for its potential therapeutic effects in various medical conditions, particularly in the field of oncology.
Mechanism of Action[edit | edit source]
JNJ-26146900 is designed to target specific pathways involved in the proliferation and survival of cancer cells. It acts as a selective inhibitor of certain kinases that are overexpressed in various types of cancer. By inhibiting these kinases, JNJ-26146900 aims to disrupt the signaling pathways that promote tumor growth and survival.
Clinical Development[edit | edit source]
The clinical development of JNJ-26146900 involves multiple phases of clinical trials. These trials are conducted to evaluate the safety, efficacy, and optimal dosing of the drug in patients with different types of cancer.
Phase I Trials[edit | edit source]
Phase I trials of JNJ-26146900 focus on assessing the safety profile of the drug in a small group of patients. These trials help determine the maximum tolerated dose and identify any potential side effects.
Phase II Trials[edit | edit source]
In Phase II trials, the efficacy of JNJ-26146900 is evaluated in a larger cohort of patients. These trials aim to provide preliminary data on the drug's effectiveness in treating specific types of cancer.
Phase III Trials[edit | edit source]
Phase III trials are large-scale studies that compare JNJ-26146900 to standard treatments. These trials are crucial for determining the drug's overall benefit-risk profile and are necessary for regulatory approval.
Potential Indications[edit | edit source]
JNJ-26146900 is being investigated for use in several types of cancer, including but not limited to:
Safety and Side Effects[edit | edit source]
As with any investigational drug, JNJ-26146900 may have side effects. Commonly reported side effects in clinical trials include:
- Fatigue
- Nausea
- Diarrhea
- Skin rash
Serious adverse events are monitored closely, and the safety data is continuously reviewed by regulatory authorities.
Regulatory Status[edit | edit source]
As of the latest update, JNJ-26146900 is in the clinical trial phase and has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
